Back to today’s briefing

Story perspectives

Taiwan's AP-402: A Breakthrough in HER2+ Cancer Treatment

5/22/2025

43 5

Summary

Story summary

Taiwan's AP Biosciences Inc. is making strides with its innovative bispecific antibody, AP-402, designed to combat HER2-resistant tumors. As some cancers cleverly evade traditional HER2-targeted therapies by modifying the HER2 receptor, AP-402 offers hope for effectively treating these challenging HER2+ cancers, potentially transforming patient outcomes.

1 of 1

Story summary

Taiwan's AP Biosciences Inc. is making strides with its innovative bispecific antibody, AP-402, designed to combat HER2-resistant tumors. As some cancers cleverly evade traditional HER2-targeted therapies by modifying the HER2 receptor, AP-402 offers hope for effectively treating these challenging HER2+ cancers, potentially transforming patient outcomes.